Table 3 Sterologic Analysis in Semithin Sections

From: Renal Damage in the SHR/N-cp Type 2 Diabetes Model: Comparison of an Angiotensin-Converting Enzyme Inhibitor and Endothelin Receptor Blocker

Animal group

LV (mm/mm3)

Podocyte number per glomerulus

Mean podocyte volume (μm3)

Mean mesangial cell volume (μm3)

Mean endothelial cell volume (μm3)

Nondiabetic SHR/N-cp (n = 9)

9137 ± 843†

92 ± 11.2†

9470 ± 4077†

935 ± 368†

1253 ± 161§

Nondiabetic SHR/N-cp + ETA-RB (n = 8)

9698 ± 1451†

77 ± 12

10,181 ± 1,030†

726 ± 149†

1020 ± 102†

Nondiabetic SHR/N-cp + ACE-i (n = 13)

9185 ± 938†

82 ± 9.9‡

9898 ± 1451†

939 ± 93†

1326 ± 119§

Diabetic SHR/N-cp (n = 7)

7383 ± 425*

61 ± 3.4*†

15,519 ± 3,011*‡

1223 ± 101

2213 ± 301*‡

Diabetic SHR/N-cp + ETA-RB (n = 9)

8252 ± 787*‡

57 ± 8.4*‡

16,703 ± 2,664*‡

1050 ± 220†

1129 ± 171†

Diabetic SHR/N-cp + ACE-i (n = 12)

9963 ± 1280†

79 ± 11.4†

9991 ± 3010†

867 ± 135†

1090 ± 277†

ANOVA

p < 0.05

p < 0.05

p < 0.05

p < 0.05

p < 0.05

  1. *p < 0.05 vs nondiabetic SHR/N-cp.
  2. †p < 0.05 vs diabetic SHR/N-cp.
  3. ‡‡ p < 0.05 vs diabetic SHR/N-cp + ACE.
Back to article page